Unlock the power of desire with PT-141 (Vyleesi), the FDA-approved solution for hypoactive sexual desire disorder (HSDD) in premenopausal women. Experience heightened arousal and intimacy with this groundbreaking on-demand treatment designed to elevate your sexual wellness.
Mechanism
PT-141 activates key melanocortin receptors in the brain that drive sexual desire and arousal. By stimulating these neural pathways, it not only boosts your libido but also promotes essential physiological responses, making intimacy more fulfilling.
Research
Supported by two pivotal Phase 3 trials, PT-141 has proven efficacy in enhancing sexual desire and reducing distress in premenopausal women. While its use in men is anecdotal and lacks extensive clinical backing, the results in women speak volumes about its potential impact on sexual health.
Synergies
When combined with PDE5 inhibitors in men or hormonal therapies in women, PT-141 can amplify overall effectiveness. Ben IQ personalizes your approach by analyzing YOUR labs and goals for optimal results.
Trade-Offs
PT-141 is a non-hormonal game changer for sexual desire, but be aware of potential side effects like nausea. Individual health factors, especially cardiovascular issues, require careful consideration. Your health, your data, your decisions.